SH3PXD2B: A Promising Adapter Protein Target for Drug Development

Target Name: SH3PXD2B

NCBI ID: G285590

SH3PXD2B

SH3PXD2B: A Promising Adapter Protein Target for Drug Development

Introduction

SH3PXD2B, also known as adapter protein HOFI, is a protein that plays a crucial role in the process of protein-protein interactions (PPIs) and is a potential drug target and biomarker. SH3PXD2B is a member of the SH3PX family of proteins, which are known for their ability to interact with a wide range of protein partners. The SH3PXD2B protein has been shown to interact with several protein partners, including the protein known as IDH1 (importin derive from homolog 1), which is a key regulator of cell proliferation and survival.

The Role of SH3PXD2B in PPIs

SH3PXD2B is involved in the formation of PPIs by its ability to interact with the protein partner through a process called forming partner. Chaperone formation is a special protein-protein interaction that usually involves two proteins forming a chaperone complex through non-covalent bonds. This interaction is a key factor in protein function because it can lead to changes in protein function, thereby affecting cell biological processes.

Interaction of SH3PXD2B and IDH1

IDH1 is a protein related to the cell cycle and plays an important role in the cell cycle. Studies have shown that the activity of IDH1 is affected by multiple factors, including protein-protein interactions (PPIs). SH3PXD2B is the protein chaperone of IDH1. By forming a chaperone complex, SH3PXD2B can interact with IDH1, thereby affecting the activity of IDH1.

Biological functions of SH3PXD2B

According to research, SH3PXD2B plays an important role in the occurrence and development of tumors. Studies have found that the expression level of SH3PXD2B is positively correlated with the prognosis of various cancers, including lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of SH3PXD2B is also positively correlated with tumor invasion and metastasis, which indicates that SH3PXD2B plays an important role in tumor invasion and metastasis.

Pharmacological significance of SH3PXD2B

Because SH3PXD2B plays an important role in tumor occurrence and development, it is considered a potential drug target. By inhibiting the activity of SH3PXD2B, it is possible to slow down or prevent tumor invasion and metastasis, thereby improving the survival rate of tumor patients.

in conclusion

SH3PXD2B is a protein that plays an important role in tumor occurrence and development. By inhibiting the activity of SH3PXD2B, tumor invasion and metastasis can be slowed down or prevented, thereby improving the survival rate of tumor patients. Therefore, SH3PXD2B is a potential drug target and an important research object.

Protein Name: SH3 And PX Domains 2B

Functions: Adapter protein involved in invadopodia and podosome formation and extracellular matrix degradation. Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1- or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. Plays a role in mitotic clonal expansion during the immediate early stage of adipocyte differentiation (By similarity)

The "SH3PXD2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3PXD2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets